Leerink Partnrs Analysts Lift Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a report released on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will earn ($0.05) per share for the quarter, up from their previous forecast of ($0.08). The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS and FY2026 earnings at $0.48 EPS.

IRWD has been the topic of a number of other research reports. JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a report on Thursday, January 30th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Craig Hallum lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 16th. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Finally, Citizens Jmp lowered Ironwood Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 14th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $4.78.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock opened at $0.68 on Monday. The business’s fifty day moving average price is $1.12 and its 200 day moving average price is $2.61. Ironwood Pharmaceuticals has a 1-year low of $0.59 and a 1-year high of $7.11. The firm has a market capitalization of $110.71 million, a PE ratio of -22.81 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $41.14 million for the quarter, compared to analyst estimates of $67.02 million.

Institutional Trading of Ironwood Pharmaceuticals

Large investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at $36,000. Journey Strategic Wealth LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at $45,000. Simplicity Wealth LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the first quarter valued at $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at $47,000. Finally, Xponance Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.